Inhibiting mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex

Area of Science:

• Cellular Biology
• Neuroscience
• Pharmacology

Background:

• Autophagy, a cellular degradation process, is crucial for maintaining cellular health.
• Defective autophagy in the brain is implicated in neurodegenerative diseases like Alzheimer's disease.
• The protein kinase mTOR (mechanistic target of rapamycin) regulates autophagy, but its inhibition's effect on brain autophagy remains debated.

Purpose of the Study:

• To investigate whether inhibiting mTOR can enhance autophagy in the brain.
• To assess the efficacy of the mTOR inhibitor AZD2014 in promoting brain autophagy in vivo.

Main Methods:

• Mice were treated with the mTOR inhibitor AZD2014 via intraperitoneal injection for seven days.
• mTOR complex 1 (mTORC1) activity was measured in liver and brain tissues.
• Autophagic activity was assessed using immunoblotting for LC3 (microtubule-associated proteins-1A/1B light chain 3B) and autophagic flux measurements in transgenic mice.

Main Results:

• AZD2014 treatment decreased mTORC1 activity in both the liver and brain.
• Autophagic activity significantly increased in both organs following AZD2014 administration.
• Changes in LC3 levels correlated with altered mTOR activity, supporting the drug's mechanism.

Conclusions:

• Inhibition of mTOR with AZD2014 effectively promotes autophagy in the brain.
• This study demonstrates a viable strategy for enhancing brain autophagy.
• Targeting mTOR could be a valuable therapeutic approach for neurodegenerative conditions characterized by defective autophagy.